BioCryst Wins Flu Drug Contract, Stock Jumps More Than 10%

The Department of Health and Human Services said it has awarded a $102.6 million, four-year contract to BioCryst Pharmaceuticals for advanced development of its influenza antiviral drug, peramivir. BioCryst shares soared on the news, trading as high as $12.50 -- a 12% gain over yesterday's closing price.

In laboratory studies to date, peramivir has shown effectiveness against a number of influenza strains, the department said in a statement.

HHS added that funding provided under the new contract will support further studies to determine if peramivir can be an effective treatment for seasonal and life-threatening influenza.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More*

Don't Miss

U.S. Video

  • CNBC's Tyler Mathisen looks back at the week's top business and financial stories. The markets were closed for Thanksgiving, but did manage to hit new highs. Low oil prices gave consumers more money to spend for Black Friday.

  • Cyber Monday deals on Walmart's website on Dec. 2, 2013.

    CNBC's Tyler Mathisen looks ahead to what are likely to be next week's top stories. The jobs report comes out this week, as do auto sales. And the Rockefeller Center Christmas tree is lit.

  • Following last week's wild energy ride, analysts expect oil prices to continue to drop during the holiday season. CNBC's Patti Domm reports.